Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ONTX |
---|---|---|
09:32 ET | 500 | 0.9901 |
09:34 ET | 13129 | 1.0049 |
09:38 ET | 248 | 1 |
09:41 ET | 100 | 1.01 |
09:43 ET | 2499 | 1.02 |
09:50 ET | 7422 | 1.0105 |
09:56 ET | 1973 | 1.04 |
09:57 ET | 4431 | 1.03 |
09:59 ET | 800 | 1.0205 |
10:01 ET | 2500 | 1.021 |
10:03 ET | 350 | 1.03 |
10:08 ET | 2150 | 1.02 |
10:10 ET | 1730 | 1.0369 |
10:12 ET | 5287 | 1.06 |
10:14 ET | 21092 | 1.05 |
10:15 ET | 400 | 1.05 |
10:17 ET | 19620 | 1.0699 |
10:19 ET | 2384 | 1.085 |
10:21 ET | 3460 | 1.0971 |
10:24 ET | 1424 | 1.085 |
10:26 ET | 4215 | 1.05 |
10:33 ET | 2205 | 1.0501 |
10:35 ET | 3595 | 1.0783 |
10:37 ET | 950 | 1.045 |
10:42 ET | 600 | 1.05 |
10:44 ET | 8050 | 1.04 |
10:51 ET | 4075 | 1.04 |
10:55 ET | 2000 | 1.055 |
10:57 ET | 300 | 1.0616 |
11:04 ET | 1110 | 1.0501 |
11:09 ET | 260 | 1.0669 |
11:11 ET | 125 | 1.06 |
11:13 ET | 330 | 1.05 |
11:29 ET | 4800 | 1.05 |
11:38 ET | 350 | 1.05 |
11:40 ET | 2008 | 1.05 |
11:42 ET | 500 | 1.05 |
11:44 ET | 1600 | 1.04 |
11:47 ET | 735 | 1.02 |
11:51 ET | 147 | 1.0378 |
11:54 ET | 1674 | 1.0101 |
12:00 ET | 5489 | 1.01 |
12:05 ET | 1388 | 1.02 |
12:07 ET | 100 | 1.02 |
12:09 ET | 19232 | 1.05 |
12:12 ET | 4599 | 1.0574 |
12:16 ET | 248 | 1.06 |
12:18 ET | 100 | 1.0582 |
12:21 ET | 1000 | 1.058 |
12:25 ET | 2000 | 1.05 |
12:27 ET | 500 | 1.0501 |
12:30 ET | 1900 | 1.0502 |
12:56 ET | 400 | 1.05 |
12:57 ET | 400 | 1.0358 |
01:15 ET | 340 | 1.05 |
01:17 ET | 1000 | 1.0485 |
01:19 ET | 100 | 1.045 |
01:24 ET | 200 | 1.04 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Onconova Therapeutics Inc | 20.4M | -1.1x | --- |
Calidi Biotherapeutics Inc | 20.2M | -0.9x | --- |
NuCana PLC | 16.2M | -0.4x | --- |
Eom Pharmaceutical Holdings Inc | 20.7M | -6.2x | --- |
AIM ImmunoTech Inc | 21.6M | -1.1x | --- |
NeuroBo Pharmaceuticals Inc | 21.1M | -0.6x | --- |
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing products for patients with cancer. It has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. It has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. It is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.4M |
---|---|
Revenue (TTM) | $226.0K |
Shares Outstanding | 21.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.37 |
EPS | $-0.96 |
Book Value | $1.35 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 90.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,544.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.